At the 4th China International Consumer Goods Expo held this year, China International Medical and Health Co., Ltd. (referred to as Sinopharm International) unveiled over 300 products from over 40 brands and released new products at the Expo for three consecutive times. Among them, the oral aging inhibitor RESTORIN, launched by well-known multinational pharmaceutical company Seragon, integrating multiple cutting-edge aging intervention technologies from Harvard University and Mayo Medical Center, was also exhibited at this year's Consumer Expo, attracting attention. It is reported that the product was introduced to China by Sinopharm's joint venture with Sinogen, Sinopharm's Sinogen. Currently, it has been listed on the official platform of Sinopharm's entire range of life and health products - Sinopharm Daji, as well as e-commerce platforms such as Tmall and JD.com. In recent years, Sinopharm International has vigorously developed strategic emerging industries and future health industries around the entire human life cycle, focusing on cultivating innovative enterprises in new tracks, technologies, platforms, and mechanisms, and striving to build a life and health industry chain. Its business has covered the development of strategic emerging industries and international operation of medicine, the big health industry, duty-free business, medical and health care, and other fields. As the exclusive licensor of core technologies and patents in the field of aging inhibition and natural lifespan extension at research institutes such as Harvard University, Mayo Medical Center, and Scripps Institute, Sanogen already has a series of technologies covering mTOR pathway inhibition, mitochondrial metabolism optimization, targeted clearance of aging cells (Sinolysis), Sirtuin activation, NAD+enhancement, and more. The preclinical trial of the new generation of aging inhibitor SRN-901 initiated by Senogen in 2021 has achieved many breakthrough results in various fields, including full transcriptome analysis at the cellular and molecular level, proteomics, metabolomics, physiological blood markers, physical fitness, cognitive ability, and natural lifespan differences, as well as machine learning modeling at the bioinformatics level. The technology source of the Senogen aging inhibitor Ruituoling introduced by Chinese medicine this time is SRN-901. According to experimental data released by Senogen, in aging intervention experiments targeting middle-aged mice (equivalent to humans in their 50s), the remaining lifespan of middle-aged mice in the SRN-901 experimental group was improved. "Sinopharm and Sinogen have a profound understanding of market demand, and have conducted in-depth cooperation in the field of aging intervention, jointly committed to the research and commercialization of aging intervention technology, hoping to help elderly people delay aging and improve their quality of life." Senogan executives stated that the launch of Ruituoling aligns with the consumer demand for "healthy aging", and the cooperation between Sinopharm and Senogan will further accelerate the development of the domestic aging intervention industry. For future development plans, Sinopharm Sinogen has stated that it will focus on technological innovation, uphold the advantages and resources of Sinopharm and Sinogen, continue to deeply cultivate the field of aging intervention, research and develop more forward-looking and driving technologies and products to better meet the health and lifestyle needs of the public. (Lai Xin She)